Please login to the form below

naltrexone

This page shows the latest naltrexone news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result.

Latest news

Takeda files block on generic diet pill launch

The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).
Saxenda debuts in US with $1,000-a-month price tag

s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover.
Positive data in Saxenda diabetes prevention study

the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
CHMP thumbs up for Novo's obesity drug Saxenda

new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
Orexigen’s obesity pill Mysimba set for European approval

The drug is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, a drug designed to prevent drug dependence. ... The CHMP has recommended a marketing authorisation for Mysimba (naltrexone/bupropion) for weight

More from news
Approximately 5 fully matching, plus 24 partially matching documents found.

Featured jobs

Systematic Review Lead- London: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director or Senior Account Director: Salary TBC

Healthcare PR Senior Account Manager: Salary TBC

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Healthcare Advertising Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Graduate Scientific Editor: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Associate Scientific Director: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....